SBIR/STTR Research Award
Engineered bacteriophage as a platform to deliver nucleic acid based therapeutics to bacteria to disperse biofilms in implant-associated infections such as prosthetic joint infections
Award amount
$263,500Program and phase
SBIR · Phase IAward year
2016Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- EnBiotix, Inc.
- Proposal award date
- 2016-07-01
- Contract end date
- 2017-12-31
- UEI
- Not reported
- Solicitation number
- PA14-307
- Topic code
- NIAID
Research abstract
Abstract
Bacteriophages are viruses that specifically and solely infect bacteria and are a natural platform
delivery system of genetic information encoded by nucleic acids to bacteria Lytic bacteriophages do not
integrate their DNA into the bacterial chromosome but replicate independently and ultimately kill their host
bacteria In the early andapos s bacteriophages were used to fight infections in humans but largely fell to the
wayside after the discovery of antibiotics in the andapos s Only in Eastern Europe and the former Soviet
Republics are bacteriophages still considered as effective therapeutic agents With the antibiotic
armamentarium currently challenged by the combination of increasing antibiotic resistance and a dearth of new
investment and discovery in new classes of antibiotics natural bacteriophage therapy is experiencing a
renaissance Along with this renaissance in bacteriophage therapy advances in systems and synthetic biology
now enable exquisite engineering of bacteriophage genomes to introduce nucleic acid therapeutics to alter the
physiology pathogenicity virulence and antibiotic sensitivity of targeted bacterial species Bacteriophage can
thus be designed to deliver genetic payloads to achieve specific desired effects such as enhancing antibiotic
killing by genetic repression of DNA repair mechanisms the self generation of antimicrobial peptides and
proteins and expression of enzymes to degrade bacterial biofilms
Biofilm associated infections are particularly difficult to treat due to the physical and physiological
barriers biofilms pose to antimicrobial agents and host defenses Biofilms are central to the pathogenesis of
many serious clinical infections and often colonize foreign body surfaces such as in prosthetic joint infections
PJI The annual cost of PJI to US hospitals in was $ M and is projected to increase to $ B by
Much of this cost is for surgical replacement of infected prostheses due to the failure of medical
treatment Failure of medical treatment is most problematic in device infections caused by S aureus due to
its virulence and rapid biofilm formation This proposal seeks to improve medical treatment for PJI caused by
S aureus by utilizing engineered bacteriophage to deliver nucleic acid therapeutics to the bacteria encoding
biofilm degrading enzymes to disperse the protective biofilm Removal of the biofilm will reduce the inherent
tolerance of bacteria to antimicrobial therapy improve medical treatment outcomes and thereby reduce
surgical intervention prosthesis replacement and the associated health costs and patient burden Project Narrative
Bacteriophages are viruses that infect and kill only bacteria Using synthetic biology bacteriophages are a
natural platform for delivering engineered genes to bacteria to alter their physiology and function to make
bacteria more sensitive to antibiotics This project will engineer a bacteriophage to deliver gene payloads
encoding enzymes to remove the biofilm a surface associated aggregate of bacterial cells in a gelatin like
slime that protects bacteria from antibiotics and host defense on prosthetic joints i e knees and hips
infected with Staphylococcus aureus as an adjuvant to standard antibiotic therapy
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients